ClariVest Asset Management LLC trimmed its holdings in shares of Bausch Health Companies Inc. (NYSE:BHC – Get Rating) by 12.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 235,194 shares of the company’s stock after selling 34,350 shares during the quarter. ClariVest Asset Management LLC’s holdings in Bausch Health Companies were worth $6,506,000 at the end of the most recent quarter.
A number of other institutional investors have also bought and sold shares of the business. Laurion Capital Management LP increased its position in Bausch Health Companies by 10.9% during the third quarter. Laurion Capital Management LP now owns 7,536,780 shares of the company’s stock worth $209,899,000 after buying an additional 741,378 shares during the last quarter. Clear Street LLC acquired a new position in Bausch Health Companies during the fourth quarter worth $102,158,000. Bank of Montreal Can increased its position in Bausch Health Companies by 0.9% during the fourth quarter. Bank of Montreal Can now owns 3,403,767 shares of the company’s stock worth $94,575,000 after buying an additional 29,319 shares during the last quarter. Canyon Capital Advisors LLC increased its position in Bausch Health Companies by 20.6% during the third quarter. Canyon Capital Advisors LLC now owns 2,956,000 shares of the company’s stock worth $82,325,000 after buying an additional 505,000 shares during the last quarter. Finally, Redwood Capital Management LLC increased its position in Bausch Health Companies by 4.3% during the third quarter. Redwood Capital Management LLC now owns 2,403,137 shares of the company’s stock worth $66,927,000 after buying an additional 100,000 shares during the last quarter. 73.38% of the stock is currently owned by hedge funds and other institutional investors.
Several equities analysts have commented on BHC shares. BMO Capital Markets lowered their target price on shares of Bausch Health Companies from $26.00 to $15.00 in a research report on Wednesday, May 11th. TheStreet cut shares of Bausch Health Companies from a “c-” rating to a “d+” rating in a report on Monday, March 28th. Royal Bank of Canada decreased their price target on shares of Bausch Health Companies from $21.00 to $17.00 and set an “outperform” rating for the company in a report on Sunday, May 15th. Bank of America decreased their price target on shares of Bausch Health Companies from $25.00 to $12.00 in a report on Wednesday, May 11th. Finally, StockNews.com cut shares of Bausch Health Companies from a “buy” rating to a “hold” rating in a report on Wednesday, May 11th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, Bausch Health Companies presently has a consensus rating of “Buy” and a consensus target price of $20.80.
Bausch Health Companies (NYSE:BHC – Get Rating) last released its earnings results on Wednesday, February 23rd. The company reported $1.27 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.19. Bausch Health Companies had a negative net margin of 4.89% and a negative return on equity of 649.29%. The business had revenue of $2.20 billion during the quarter, compared to analysts’ expectations of $2.21 billion. During the same quarter last year, the company earned $1.33 earnings per share. The firm’s revenue was down .8% on a year-over-year basis. Sell-side analysts predict that Bausch Health Companies Inc. will post 4.15 EPS for the current fiscal year.
In related news, insider Joseph F. Gordon sold 3,889 shares of the stock in a transaction dated Tuesday, March 8th. The shares were sold at an average price of $21.76, for a total value of $84,624.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Robert Spurr sold 1,595 shares of the firm’s stock in a transaction dated Thursday, April 14th. The stock was sold at an average price of $22.19, for a total transaction of $35,393.05. Following the transaction, the insider now owns 90,506 shares of the company’s stock, valued at approximately $2,008,328.14. The disclosure for this sale can be found here. In the last quarter, insiders sold 16,668 shares of company stock valued at $378,570. 13.75% of the stock is owned by corporate insiders.
Bausch Health Companies Profile (Get Rating)
Bausch Health Companies Inc, together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products.
- Get a free copy of the StockNews.com research report on Bausch Health Companies (BHC)
- Short-Covering Begins In Big Lots
- Institutions Ring The Register On Toll Brothers Stock
- Agilent Technologies Is Bottoming But Don’t Buy It Yet
- Dick’s Sporting Goods Falls Flat On Weak Guidance
- Two Retailers, One To Buy And One To Avoid
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.